Insider · CIK 0001862146
Christopher Durant Turner
Files at NUVL (Nuvalent, Inc.). First filing Jan 7, 2026, latest Jan 7, 2026.
In brief
Christopher Durant Turner files SEC Form 4 as officer at NUVL (Nuvalent, Inc.). Since Jan 7, 2026, Christopher Durant Turner has reported 0 open-market buys worth $0 and 1 open-market sell worth $721k, the latest filed on Jan 7, 2026.
A track record needs three past buys with six months of prices behind them; Christopher Durant Turner has 0, so none is measured yet.
The newest scored trade: sold $721k of NUVL on Jan 5, 2026, filed Jan 7, 2026, scored 36 (weak), under a 10b5-1 plan. In the last 12 months: 0 buys worth $0 and 1 sell worth $721k.
Signals
This insider’s open-market buys and sells, scored.
| Score | Company | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 36Weak | Nuvalent, Inc. | $721k 7,417 shares | -12% | - |
Planned sales
Form 144 notices this insider filed before selling restricted or control stock, newest first.
| Filed | Company | Shares | Value | Sale date | Past 3 months |
|---|---|---|---|---|---|
| Jan 5, 2026 | NUVL NUVALENT, INC. | 4,236 0.01% of outstanding | $412k | Jan 5, 2026 | none |
| Jan 6, 2025 | NUVL Nuvalent, Inc. | 4,250 0.01% of outstanding | $343k | Jan 6, 2025 | none |
Transactions
Every row this insider has filed, 20 in all, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Jul 15, 2026 | NUVL Nuvalent, Inc. | UTender of shares Class A Common Stock | -31,530 | $124.00 | $3.9M | 0 | Jul 15, 2026 |
| Jul 15, 2026 | NUVL Nuvalent, Inc. | DDisposition to issuer Class A Common Stock - Restricted Stock Units | -41,100 | - | - | 0 | Jul 15, 2026 |
| Jul 15, 2026 | NUVL Nuvalent, Inc. | AGrant or award Class A Common Stock - Performance Stock Units | +14,350 | $0.00 | $0 | 14,350 | Jul 15, 2026 |
| Jul 15, 2026 | NUVL Nuvalent, Inc. | DDisposition to issuer Class A Common Stock - Performance Stock Units | -14,350 | - | - | 0 | Jul 15, 2026 |
| Jul 15, 2026 | NUVL Nuvalent, Inc. | DDisposition to issuer Stock Option (Right to Buy)derivative | -303,105 | - | - | 0 | Jul 15, 2026 |
| Jul 15, 2026 | NUVL Nuvalent, Inc. | DDisposition to issuer Stock Option (Right to Buy)derivative | -2,835 | - | - | 0 | Jul 15, 2026 |
| Jul 15, 2026 | NUVL Nuvalent, Inc. | DDisposition to issuer Stock Option (Right to Buy)derivative | -107,000 | - | - | 0 | Jul 15, 2026 |
| Jul 15, 2026 | NUVL Nuvalent, Inc. | DDisposition to issuer Stock Option (Right to Buy)derivative | -144,200 | - | - | 0 | Jul 15, 2026 |
| Jul 15, 2026 | NUVL Nuvalent, Inc. | DDisposition to issuer Stock Option (Right to Buy)derivative | -47,500 | - | - | 0 | Jul 15, 2026 |
| Jul 15, 2026 | NUVL Nuvalent, Inc. | DDisposition to issuer Stock Option (Right to Buy)derivative | -37,500 | - | - | 0 | Jul 15, 2026 |
| Jul 15, 2026 | NUVL Nuvalent, Inc. | DDisposition to issuer Stock Option (Right to Buy)derivative | -17,500 | - | - | 0 | Jul 15, 2026 |
| Jan 5, 2026 | NUVL Nuvalent, Inc. | SOpen-market sale Class A Common Stock10b5-1 | -871 | $96.06 | $84k | 61,676 | Jan 7, 2026 |
| Jan 5, 2026 | NUVL Nuvalent, Inc. | SOpen-market sale Class A Common Stock10b5-1 | -1,119 | $96.85 | $108k | 60,557 | Jan 7, 2026 |
| Jan 5, 2026 | NUVL Nuvalent, Inc. | SOpen-market sale Class A Common Stock10b5-1 | -1,929 | $97.96 | $189k | 58,628 | Jan 7, 2026 |
| Jan 5, 2026 | NUVL Nuvalent, Inc. | SOpen-market sale Class A Common Stock10b5-1 | -317 | $98.52 | $31k | 58,311 | Jan 7, 2026 |
| Jan 6, 2026 | NUVL Nuvalent, Inc. | SOpen-market sale Class A Common Stock10b5-1 | -1,321 | $96.75 | $128k | 56,990 | Jan 7, 2026 |
| Jan 6, 2026 | NUVL Nuvalent, Inc. | SOpen-market sale Class A Common Stock10b5-1 | -1,635 | $97.33 | $159k | 55,355 | Jan 7, 2026 |
| Jan 6, 2026 | NUVL Nuvalent, Inc. | SOpen-market sale Class A Common Stock10b5-1 | -225 | $98.40 | $22k | 55,130 | Jan 7, 2026 |
| Jan 7, 2026 | NUVL Nuvalent, Inc. | AGrant or award Class A Common Stock10b5-1 | +17,500 | $0.00 | $0 | 72,630 | Jan 7, 2026 |
| Jan 7, 2026 | NUVL Nuvalent, Inc. | AGrant or award Stock Option (Right to Buy)derivative10b5-1 | +17,500 | $0.00 | $0 | 17,500 | Jan 7, 2026 |
Questions about Christopher Durant Turner
Answered from the filings on this page, as of the latest one.
Is Christopher Durant Turner buying or selling?
In the last 12 months Christopher Durant Turner reported 0 open-market buys worth $0 and 1 open-market sell worth $721k on SEC Form 4; the latest was sold $721k of NUVL on Jan 5, 2026. Grants, option exercises and tax withholding are not counted.
How did Christopher Durant Turner's past buys perform?
Not measured yet. InsiderTell needs three past buys with six months of prices to publish a track record, and Christopher Durant Turner has 0.
Where does Christopher Durant Turner file Form 4?
Christopher Durant Turner has filed Form 4 at NUVL (Nuvalent, Inc.) as Chief Medical Officer. A Form 4 is required of officers, directors and holders of more than 10% of a share class within two business days of a trade.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.